Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Truscreen GroupNZSE:TRU Buyback Yield % is -21.12 as of Jul. 31, 2026. The stock has 4 warning signs investors should review. Among 347 Medical Devices & Instruments companies, Truscreen Group ranks worse than 78.96% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Truscreen Group's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:TRU vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Truscreen Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Truscreen Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (NZSE:TRU) has a Buyback Yield % of -21.12 as of Jul. 31, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Truscreen Group and its competitors. According to the industry distribution chart, Truscreen Group ranks #274 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 79%.
Is Truscreen Group's Buyback Yield % too high?
Truscreen Group's current Buyback Yield % is -21.12. Based on the distribution chart, Truscreen Group ranks #274 out of 347 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Truscreen Group's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #274 out of 347 companies for Buyback Yield %. This places Truscreen Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Truscreen Group and its competitors. Truscreen Group's current Buyback Yield % is -21.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (NZSE:TRU) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% below its estimated fair value. The current Buyback Yield % is -21.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Truscreen Group (NZSE:TRU), the current Buyback Yield % is -21.12 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:TRU has been successfully added to your 
